Preparation and purification of antibody-enzyme conjugates for therapeutic applications

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 289-301

  Melton, Roger G ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

ADEPT; antibody enzyme conjugates; conjugate; coupling; heterobifunctional reagents; purification

Indexed keywords

ANTIBODIES; CHEMICAL MODIFICATION; COMPOSITION; ENZYMES; ETHERS; MOLECULAR WEIGHT; PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; SULFUR COMPOUNDS;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY ENZYME CONJUGATES; CHEMICAL CONJUGATION; HETEROBIFUNCTIONAL COUPLING AGENTS; THIOETHER; THIOLATION;

CONTROLLED DRUG DELIVERY;

AMINO ACID; ANTIBODY; ANTIBODY CONJUGATE; DISULFIDE; ENZYME; HYBRID PROTEIN; LYSINE; SULFIDE; TOXIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CHEMICAL REACTION; CONJUGATION; ELECTRICITY; GEL PERMEATION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PURIFICATION; REVIEW; TECHNIQUE; TECHNOLOGY;

EID: 0030589521     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00447-4     Document Type: Review

References (62)

1. [1] Boorsma, D.M. and Streefkerk, J.G. (1979) Periodate or glutaraldehyde for preparing peroxidase conjugates? J. Immunol. Methods 30, 245-255.
2. [2] Thorpe, P.E. and Ross, W.C.J. (1982) The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol. Rev. 62, 119-158.
3. [3] Muzykantov, V.R., Trubetskaya, O.V., Puchnina, E.A., Sakharov, D.V. and Domogatsky, S.P. (1990) Cytotoxicity of glucose oxidase conjugated with antibodies to target cells: killing efficiency depends on the conjugate internalization. Biochim. Biophys. Acta 1053, 27-31.
4. [4] Muzykantov, M.R., Sakharov, D.V., Sinitsyn, V.V., Domogatsky, S.P., Goncharov, N.V. and Danilov, S.M. (1988) Specific killing of human endothelial cells by antibody-conjugated glucose oxidase. Anal. Biochem. 169, 383-389.
5. [5] Stanislawski, M., Rousseau, V., Goavec, M. and Ito, H. (1989) Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: in vitro killing effectiveness in a mouse plasmacytoma cell model. Cancer Res. 49, 5497-5504.
6. [6] Philpott, G.W., Shearer, W.T., Bower, R.J. and Parker, C.W. (1973) Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J. Immunol. 111, 921-929.
7. [7] Wines, B.D. and Easterbrooksmith, S.B. (1991) The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues. Mol. Immunol. 28, 855-863.
8. [8] Goshorn, S.C., Svensson, H.P., Kerr, D.E., Somerville, J.E., Senter, P.D. and Fell, H.P. (193) Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Res. 53, 2123-2127.
9. [9] Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M. and Seemann, G. (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234-238.
10. [10] Takahashi, H., Igarishi, T., Shimada, I. and Arata, Y. (1991) Preparation of the Fv fragment from a short-chain mouse IgG2a anti-dansyl monoclonal antibody and use of selectively deuterated Fv analogues for two-dimensional H-1 NMR analyses of the antigen-antibody interactions. Biochemistry 30, 2840-2847.
11. 2 suitable for clinical use from mouse IgG1. Mol. Immunol. 28, 69-77.
12. [12] Milenic, D.E., Esteban, J.M. and Colcher, D. (1989) Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J. Immunol. Methods 120, 71-83.
13. 2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging. J. Immunol. Methods 110, 229-236.
14. [14] Parham, P., Androlewicz, M.J., Brodsky, F.M., Holmes, N.J. and Ways, J.P. (1982) Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J. Immunol. Methods 53, 133-173.
15. [15] Eccles, S.A., Court, W.J., Box, G.A., Dean, C.J., Melton, R.G. and Springer, C.J. (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p 185. Cancer Res. 54, 5171-5177.
16. [16] Yamaguchi, Y., Kim, H., Kato, K., Masuda, K., Shimada, I. and Arata, Y. (1995) Proteolytic fragmentation with high specificity of mouse immunoglobulin G - Mapping of proteolytic cleavage sites in the hinge region. J. Immunol. Methods 181, 259-267.
17. [17] Blakey, D.C., Watson, G.J., Knowles, P.P. and Thorpe, P.E. (1987) Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 47, 947-952.
18. [18] Worrell, N.R., Cumber, A.J., Parnell, G.D., Mirza, A., Forrester, J.A. and Ross, W.C.J. (1986) Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anti-Cancer Drug Des. 1, 179-188.
19. [19] Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
20. [20] Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, R.W. and Rogers, G.T. (1990) Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br. J. Cancer 61, 659-662.
21. [21] Kerr, D.E., Garrigues, U.S., Wallace, P.M., Hellstrom, K.E., Hellstrom, I. and Senter, P.D. (1993) Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjugate Chem. 4, 353-357.
22. [22] Thorpe, P.E., Wallace, P.M., Knowles, P.P., Reif, M.G., Brown, A.N.F., Watson, G.J., Knyba, R.E., Wawrzynczak, E.J. and Blakey, D.C. (1987) New coupling agents for the synthesis of immunotoxins containing hindered disulphides with improved stability in vivo. Cancer Res. 47, 5924-5931.
23. [23] Wang, S.M., Chern, J.W., Yeh, M.Y., Ng, Y.C., Tung, E. and Roffler, S.R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzymes for cancer therapy. Cancer Res. 52, 4484-4491.
24. [24] Kerr, D.E., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellstrom, I. and Hetlstrom, K.E. (1991) Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31, 202-206.
25. [25] Shepherd, T.A., Jungheim, L.N., Meyer, D.L. and Starling, J.J. (1991) A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody beta-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. 1, 21-26.
26. [26] Meyer, D.L., Jungheim, L.N., Mikolajczyk, S.D., Shepherd, T.A., Starling, J.J. and Ahlem, C.N. (1992) Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconjugate Chem. 3, 42-48.
27. [27] Haisma, H.J., Boven, E., Vanmuijen, M., Devries, R. and Pinedo, H.M. (1992) Analysis of a conjugate between anticarcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother. 34, 343-348.
28. [28] Haisma, H.J., Boven, E., Vanmuijen, M., Dejong, J., Vandervijgh, W.J.F. and Pinedo, H.M. (1992) A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474-478.
29. [29] Esswein, A., Hanseler, E., Montejano, Y., Vitols, K.S. and Huennekens, P.M. (1991) Construction and therapeutic potential of a carboxypeptidase A/monoclonal antibody conjugate. Adv. Enzyme Regul. 31, 3-12.
30. 2. J. Immunol. Methods 158, 49-56.
31. 2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br. J. Cancer 53, 377-384.
32. [32] Carlsson, J., Drevin, H. and Axen, R. (1978) Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 173, 723-737.
33. [33] Duncan, R.J.S., Weston, P.D. and Wrigglesworth, R. (1983) A new reagent which may be used to introduce sulphydryl groups into proteins and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 132, 68-73.
34. [34] Meyer, D.L., Jungheim, L.N., Law, K.L., Mikolajczyk, S.D., Shepherd, T.A., Mackensen, D.G., Briggs, S.L. and Starling, J.J. (1993) Site-specific prodrug activation by antibody-beta-lactamase conjugates - regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956-3963.
35. [35] Sedlak, J. and Lindsay, R.H. (1968) Estimation of total, protein bound and non-protein sulphydryl groups in tissue with Ellman's reagent. Anal. Biochem. 25, 192-205.
36. [36] Mueller, B.M., Wrasidlo, W.A. and Reisfeld, R.A. (1988) Determination of the number of ∈ -amino groups available for conjugation of effector molecules to monoclonal antibodies. Hybridoma 7, 453-456.
37. [37] Murayama, A., Shimada, K. and Yamamoto, T. (1978) Modification of immunoglobulin G using specific reactivity of sugar moiety. Immunochemistry 15, 523-528.
38. [38] Leung, S.O., Losman, M.J., Govindan, S.V., Griffiths, G.L., Goldenberg, D.M. and Hansen, H.J. (1995) Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments. J. Immunol. 154, 5919-5926.
39. [39] Pillai, S. and Bachhawat, B.K. (1977) Protein-protein conjugation on a lectin matrix. Biochem. Biophys. Res. Commun. 75, 240-245.
40. 2 from Pseudomonas sp. strain RS16: Use of a novel triazine dye affinity method. Eur. J. Biochem. 148, 447-453.
41. [41] Fisch, I., Kunzi, G., Rose, K. and Offord, R.E. (1992) Site-specific modification of a fragment of a chimeric monoclonal antibody using reverse proteolysis. Bioconjugate Chem. 3, 147-153.
42. [42] Rose, K., Vilaseca, L.A., Werlen, R., Meunier, A., Fisch, I., Jones, R.L. and Offord, R.E. (1991) Preparation of well defined protein conjugates using enzyme-assisted reverse proteolysis. Bioconjugate Chem. 2, 154-159.
43. [43] Werlen, R.C., Lankinen, M., Rose, K., Blakey, D., Shuttleworth, H., Melton, R. and Offord, R.E. (1994) Site-specific conjugation of an enzyme and an antibody fragment. Bioconjugate Chem. 5, 411-417.
44. [44] Mikolajczyk, S.D., Meyer, D.L., Starling, J.J., Law, K.L., Rose, K., Dufour, B. and Offord, R.E. (1994) High field, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab′'. Bioconjugate Chem. 5, 636-646.
45. [45] Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engen, A., Diehl, V. and Pfreundschuh, M. (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/ anti-alkaline phosphatase monoclonal antibody. Cancer Res, 50, 6944-6948.
46. [46] Desutter, K. and Fiers, W. (1994) A bifunctional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. Mol. Immunol. 31, 261-267.
47. [47] Bagshawe, K.D., Sharma, S.K., Springer, C.J., Antoniw, P., Boden, J.A., Rogers, G.T., Burke, P.J., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT) - clinical report. Dis. Marker 9, 233-238.
48. [48] Sharma, S.K., Bagshawe, K.D. and Melton, R.G. (1991) Immunogenicity of antibody-enzyme conjugates in antibody directed enzyme prodrug therapy. Antibody Immunoconjugates Radiopharm. 4, 226.
49. 2 conjugate. Eur. J. Cancer 29A, 1177-1183.
50. [50] Haenseler, E., Esswein, A., Vitols, K.S., Montejano, Y., Mueller, B.M., Reisfeld, R.A. and Huennekens, F.M. (1992) Activation of methotrexate-alpha-alanine by carboxypeptidase-A monoclonal antibody conjugate. Biochemistry 31, 891-897.
51. [51] Wallace, P.M. and Senter, P.D. (1991) In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2, 349-352.
52. [52] Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M. and Senter, P.D. (1992) Monoclonal antibody beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug, Bioconjugate Chem, 3, 176-181.
53. [53] Nilson, B.H.K., Lögdberg, L., Kastern, W., Björck, L., and Äkerström, B. (1993) Purification of antibodies using protein L-binding framework structures in the light chain variable domain. J. Immunol. Methods 164, 33-40.
54. [54] Lowe, C.R., Burton, S.J., Burton, N.P., Alderton, W.K., Pitts, J.M. and Thomas, J.A. (1992) Designer dyes: 'Biomimetic' ligands for the purification of pharmaceutical proteins by affinity chromatography. Tibtech 10, 442-448.
55. [55] Knowles, P.P. and Thorpe, P.E. (1987) Purification of immunotoxins containing ricin A-chain and abrtn A-chain using blue sepharose CL6B. Anal. Biochem. 160, 440-443.
56. [56] Rodrigues, M.L., Presta, L.G., Kotts, C.E., Wirth, C., Mordenti, J., Osaka, G., Wong, W.L.T., Nuijens, A., Blackburn, B. and Carter, P. (1995) Development of a humanized disulfide-stabilized anti-beta p185(HER2) Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
57. [57] Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D. and Wallace, P.M. (1993) Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjugate Chem. 4, 334-340.
58. [58] Bessos, H., Appleyard, C., Micklen, L.R. and Pepper, D.S. (1991) Monoclonal antibody leakage from gels: effect of support, activation and eluant composition. Prep. Chromatogr. 1, 207-220.
59. [59] Hutchens, T.W. and Yip, T. (1995) Synthetic metal-binding protein surface domains for metal ion-dependent interaction chromatography. II. Immobilisation of synthetic metal-binding peptides from metal ion transport proteins as model bioactive protein surface domains. J. Chromatogr. 604, 133-141.
60. [60] Smith, D.B. and Johnson, K.S. (1988) Single-step purification of polypeptides expressed in Escherichia colt as fusions with glutathione-S-transferase. Gene 67, 31-40.
61. [61] Maina, C.V., Riggs, P.D., Grandea, A.C., III., Slatko, B.E., Moran, L.S., Tagliamonte, J.A., McReynolds, L.A. and Guan, C.D. (1988) An Esche richia coli vector to express and purify foreign proteins by fusion to and separation from maltose-binding protein. Gene 74, 365-373.
62. [62] Casey, J.L., Keep, P.A., Chester, K.A., Robson, L., Hawkins, R.E. and Begent, R.H.J. (1995) Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods 179, 105-116.